MEDIGUS (Israel) Financial Diagnostics

<div class='circular--portrait' style='background:#FF9E01;color: white;font-size:3em;padding-top: 35px;;'>MDG</div>
MDGS -- Israel Stock  

ILA 31.30  0.30  0.97%

The recent MEDIGUS price drops may encourage investors to take a closer look at the firm as it closed today at a share price of 30.5 on very low momentum in trading volume. The company directors and management were unable to exploit market volatilities in December. However, diversifying your overall positions with MEDIGUS can protect your principal portfolio during market swings. The stock standard deviation of daily returns for 30 days (very short) investing horizon is currently 3.4. The above-average volatility is mostly attributed to market volatility and speculations regarding some of the upcoming earning calls from MEDIGUS partners. This diagnostics interface makes it easy to digest most current publicly released information about MEDIGUS as well as get updates on important government artifacts including earning estimates, SEC corporate filings and announcements. This module also helps to analysis MEDIGUS price relationship with some important fundamental indicators such as market cap and management efficiency. Additionally see Stocks Correlation.


The company recorded loss per share of 0.09. MEDIGUS had not issued any dividends in recent years. The entity had a split on 2018-07-15. Medigus Ltd., a medical device company, develops, produces, and markets minimally invasive endo-surgical tools and direct visualization technology in the United States, Europe, Asia, and internationally. Medigus Ltd. was founded in 1999 and is headquartered in Omer, Israel. MEDIGUS operates under Medical Devices classification in Israel and is traded on Tel Aviv Stock Exchange. It employs 27 people. To find out more about MEDIGUS contact Christopher Rowland at 972 72 260 2200 or learn more at


MEDIGUS generates negative expected return over the last 30 days
MEDIGUS has high historical volatility and very poor performance
MEDIGUS has high likelihood to experience some financial distress in the next 2 years
The company reported revenue of 459 K. Net Loss for the year was (6.17 M) with loss before overhead, payroll, taxes, and interest of (171 K).
MEDIGUS has accumulated about 8.79 M in cash with (3.91 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.12.

Market Capitalization

The company currently falls under 'Micro-Cap' category with current market capitalization of 26.43 M.

Management Efficiency

MEDIGUS has return on total asset (ROA) of (55.04) % which means that it has lost $55.04 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of (125.98) % meaning that it generated substantial loss on money invested by shareholders.

Technical Drivers

As of the 23th of January MEDIGUS secures Mean Deviation of 2.06 and Risk Adjusted Performance of (0.012255). Compared with Fundamental Indicators, Macroaxis technical analysis interface lets you check possible technical drivers of MEDIGUS as well as the relationship between them. Strictly speaking you can use this information to find out if the firm will indeed mirror its model of past prices or the prices will eventually revert. We found nineteen technical drivers for MEDIGUS which can be compared to its peers in the industry. Please verify MEDIGUS Coefficient Of Variation, Variance and the relationship between Downside Deviation and Standard Deviation to decide if MEDIGUS is priced fairly providing market reflects its recent price of 31.3 per share.

MEDIGUS Price Movement Analysis

The output start index for this execution was nine with a total number of output elements of fifty-two. The Triangular Moving Average shows MEDIGUS double smoothed mean price over a specified number of previous prices (i.e. averaged twice). View also all equity analysis or get more info about triangular moving average overlap studies indicator.

MEDIGUS Technical and Predictive Indicators

MEDIGUS Forecast Models

Did you try this?

Run Companies Directory Now


Companies Directory

Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
All  Next Launch Module
Additionally see Stocks Correlation. Please also try Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Company logos by clearbit